stars 1 stars 2 stars 3

BIONOSTRA is a biotechnology company performing breakthrough technology for the development of biologic vaccines and gene therapy. The Company uses the many advances made in the fields of molecular biology, structural virology, genomics and organic chemistry to build up a novel pipeline of vaccine candidates designed to address therapeutic needs in the field of infectious diseases for its application in animal and human health. Additionally the company has established a cutting edge molecular biology laboratory to offer high value biotechnology services and applications. BIONOSTRA is compromised with the development of new tools and services for the final benefit of consumers and patients. BIONOSTRA has a strong research and development program focused in the adaptation of emergent molecular tools for genetic diagnosis.

Bionostra Questions

The Bionostra annual revenue was $5.1 million in 2026.

3 people are employed at Bionostra.

The NAICS codes for Bionostra are [541713, 54171, 541, 54, 5417].

The SIC codes for Bionostra are [87, 873].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users